Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).
Antonio Palumbo
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium; Onyx
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium; Onyx
Sara Bringhen
Honoraria - Celgene; Janssen
Vincent Rajkumar
No relevant relationships to disclose
Giulia Lupparelli
No relevant relationships to disclose
Saad Zafar Usmani
Consultant or Advisory Role - Celgene
Research Funding - Celgene; Millennium; Onyx
Anders Waage
Consultant or Advisory Role - Celgene; Janssen-Cilag; Mundipharma
Honoraria - Celgene; Janssen-Cilag; Mundipharma
Alessandra Larocca
Honoraria - Celgene; Janssen-Cilag
Bronno van der Holt
No relevant relationships to disclose
Pellegrino Musto
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Andrea Evangelista
No relevant relationships to disclose
Sonja Zweegman
Honoraria - Celgene; Janssen
Meletios A. Dimopoulos
Honoraria - Celgene; Onyx; Ortho Biotech
Research Funding - Genesis Pharmaceuticals
Roman Hajek
Consultant or Advisory Role - Celgene; Merck
Honoraria - Celgene; Janssen; Merck
Michele Cavo
Consultant or Advisory Role - Celgene; Janssen; Millennium; Novartis
Honoraria - Celgene; Janssen; Novartis
Sagar Lonial
Honoraria - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis; Onyx; Sanofi
Giovannino Ciccone
No relevant relationships to disclose
Mario Boccadoro
Consultant or Advisory Role - Celgene; Janssen
Research Funding - Celgene; Janssen
Bart Barlogie
No relevant relationships to disclose
Pieter Sonneveld
Consultant or Advisory Role - Celgene; Janssen; Onyx
Research Funding - Celgene; Janssen; Onyx
Philip L. McCarthy
Consultant or Advisory Role - Celgene; Onyx
Honoraria - Celgene; Janssen; Onyx